Equity to Asset ratio is calculated as total stockholders equity divided by total asset. PhaseRx's Total Stockholders Equity for the quarter that ended in Sep. 2017 was $-0.30 Mil. PhaseRx's Total Assets for the quarter that ended in Sep. 2017 was $6.04 Mil.
The historical rank and industry rank for PhaseRx's Equity-to-Asset or its related term are showing as below:
PZRXQ's Equity-to-Asset is not ranked *
in the Biotechnology industry.
Industry Median: 0.67 * Ranked among companies with meaningful Equity-to-Asset only.
PhaseRx Equity-to-Asset Historical Data
The historical data trend for PhaseRx's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of PhaseRx's Equity-to-Asset
For the Biotechnology subindustry, PhaseRx's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PhaseRx's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PhaseRx's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where PhaseRx's Equity-to-Asset falls into.
PhaseRx Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
PhaseRx's Equity to Asset Ratio for the fiscal year that ended in Dec. 2016 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PhaseRx (OTCPK:PZRXQ) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
PhaseRx Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of PhaseRx's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
PhaseRx Inc is a biopharmaceutical company. It is developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy, or i-ERT. The approach is enabled by proprietary Hybrid messenger RNA, or mRNA, Technology platform, which allows synthesis of the missing enzyme inside the cell. The product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency, or OTCD, argininosuccinate lyase deficiency, or ASL deficiency, and argininosuccinate synthetase deficiency, or ASS1 deficiency.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PZRXQ has been successfully added to your 